www.tajpharma.com

Zartemis® Gemcitabine for Injection USP
Therapeutic Indications: Non-Small Cell Lung Cancer¾ Zartemis® is indicated in combination with cisplatin for thefirst-line treatment of patients with inoperable, locally advanced (Stage IIIA or IIIB) or metastatic (Stage IV) non-small cell lung cancer.
Pancreatic Cancer¾ Zartemis® is indicated as first-line treatment for patients with locallyadvanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas. Gemzar is indicated for patients previously treated with 5-FU

ZARTEMIS®
(gemcitabine) injection

LIFE WILL WIN AT TAJ PHARMA INDIA.

ZARTEMIS® GEMCITABINE FOR INJ USP 200MG/VIAL POWDER FOR SOL
ZARTEMIS® GEMCITABINE FOR INJ, USP 1G/VIAL POWDER FOR SOL
ZARTEMIS® GEMCITABINE FOR INJ, USP 2 G/VIAL POWDER FOR SOL
ZARTEMIS® GEMCITABINE INJECTION, 38 MG/ML INTRAVENOUS SOLUTION

IT IS A CHEMOTHERAPY DRUG THAT WORKS BY SLOWING OR STOPPING THE GROWTH OF CANCER CELLS.

ZARTEMIS®
(gemcitabine) injection

Zartemis® Gemcitabine fights **cancer by preventing the growth of cancer cells, which eventually results in their destruction.** It is used to treat certain types of lung cancer, bladder cancer, breast cancer, and cancer of the pancreas.

Gemcitabine is used alone or with other treatments/medications to treat certain types of cancer (including breast, lung, ovarian, pancreatic).

Zartemis® Gemcitabine for Injection USP Powder for Solution
200 mg
Each vial contains 200 mg of gemcitabine (as the hydrochloride salt).
Nonmedicinal ingredients: mannitol, sodium acetate, and hydrochloric acid and sodium hydroxide (for pH adjustment).
1g
Each vial contains 1 g of gemcitabine (as the hydrochloride salt).
Nonmedicinal ingredients: mannitol, sodium acetate, and hydrochloric acid and sodium hydroxide (for pH adjustment).
2 g
Each vial contains 2 g of gemcitabine (as the hydrochloride salt).
Nonmedicinal ingredients: mannitol,sodium acetate, and hydrochloric acid and sodium hydroxide (for pH adjustment).

Intravenous Solution
Each mL of solution contains 38 mg of gemcitabine. Nonmedicinal ingredients: hydrochloric acid and sodium chloride (for pH adjustment).

HOW TO USE: Read the Patient Information Leaflet if available from your healthcare professional before you start receiving gemcitabine and each scheduled dose. If you have any questions, ask your healthcare professional.This medication is given by injection into a vein by a healthcare professional, usually over 30 minutes once a week or as directed by your doctor. The dosage is based on your medical condition and response to therapy.If this medication touches your skin, wash the skin immediately and completely with soap and water.

DO NOT THROW AWAY ANY MEDICINES VIA WASTEWATER OR HOUSEHOLD WASTE. ASK YOUR PHARMACIST HOW TO THROW AWAY MEDICINES YOU NO LONGER USE. THESE MEASURES WILL HELP PROTECT THE ENVIRONMENT.

CAUTION: CONTACT YOUR HEALTH CARE PROVIDER IMMEDIATELY, DAY OR NIGHT, ZARTEMIS® CAN SUPPRESS BONE MARROW FUNCTION AS MANIFESTED BY LEUKOPENIA, THROMBOCYTOPENIA AND ANEMIA , AND MYELOSUPPRESSION IS USUALLY THE DOSE-LIMITING TOXICITY.

Food and Drug Administration (FDA) approved .Prescription Only (POM)

A Taj Pharma"India Product

TAJ® PHARMA
A TAJ Enterprise

Do not store above 25°C. Keep container in the outer carton, in order to protect from light.
Zartemis® Gemcitabine for Injection USP is for intravenous use only.